W. Abenhardt

发表

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

H. Döhner, U. Jäger, M. Hallek, 2020, Leukemia.

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

H. Döhner, U. Jäger, M. Hallek, 2017, Leukemia.

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2011, British Journal of Cancer.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutations in the JAK2 and MPL Genes and their Correlation to Clinical Parameters in Patients with Chronic Myeloproliferative Disease

T. Haferlach, S. Schnittger, P. Bojko, 2009, Oncology Research and Treatment.

FDG-PET: An Important Tool in the Diagnosis of Lung Cancer

W. Abenhardt, 2007, Oncology Research and Treatment.

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms†

W. Knauf, N. Marschner, D. Meyer, 2014, Hematological oncology.

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

M. Kiechle, N. Harbeck, V. Heinemann, 2011, Oncology.

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

M. Kiechle, N. Harbeck, V. Heinemann, 2011, Oncology.

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

H. Sommer, J. Sehouli, P. Harter, 2017, Gynecologic Oncology Research and Practice.

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.

M. Lux, M. Beckmann, P. Fasching, 2018, Breast.

Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.

H. Ramroth, W. Knauf, S. Dambacher, 2022, Clinical lymphoma, myeloma & leukemia.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

M. Hallek, S. Stilgenbauer, C. Wendtner, 2017, European journal of haematology.

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

M. Stauch, V. Heinemann, C. Jackisch, 2005, Oncology.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

M. Stauch, V. Heinemann, H. Hass, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

M. Hallek, C. Wendtner, M. Kneba, 2009, British journal of haematology.

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

M. Hallek, R. Busch, B. Eichhorst, 2007 .

Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression

W. Wilmanns, H. Zwierzina, F. Gieseler, 1997, Annals of Hematology.

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression

M. Schuler, A. Bankfalvi, M. Wiesweg, 2020, Cancer medicine.

W. Knauf, N. Marschner, W. Abenhardt, 2019, European journal of haematology.

Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms

H. Slawik, W. Knauf, B. Otremba, 2020, Hematological oncology.

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

M. Lux, M. Beckmann, P. Fasching, 2018, Cancers.

[Early changes in thyroid hormones following radioiodine therapy of hyperthyroidism with reference to etiology and accompanying medication].

C. Kirsch, K. Mann, E. Moser, 1989, Klinische Wochenschrift.

Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry

M. Beckmann, P. Fasching, T. Fehm, 2018 .

Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)

M. Beckmann, P. Fasching, T. Fehm, 2019, Poster Session Abstracts.

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

F. Jänicke, V. Müller, M. Kaufmann, 2014, BMC Cancer.

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

M. Hallek, C. Wendtner, M. Kneba, 2007 .

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

H. Tesch, W. Jonat, V. Heinemann, 2011, British Journal of Cancer.

Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms

W. Knauf, R. Schnell, M. Koenigsmann, 2021, Hematological oncology.

Insulin and Diazoxide for Treatment of Cancer

M. Berger, M. Fink, W. Abenhardt, 1991 .

Treatment of Non-Transplant Patients with Multiple Myeloma: Routine Treatment by Office-Based Haematologists in Germany - Data from the Prospective Tumour Registry Lymphatic Neoplasms (TLN)

W. Knauf, A. Nusch, N. Marschner, 2014, Oncology Research and Treatment.

Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma

J. Tonn, A. Giese, C. Belka, 2016, Journal of Neuro-Oncology.

A Multicenter Prospective Randomized Trial with Assessment of Quality of Life in Patients with Metastatic Colorectal Carcinoma Comparing Interferon α-2b and Folinic Acid as Modulators of 5-Fluorouracil

E. Thiel, E. Kreuser, K. Ridwelski, 1994 .

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

H. Tesch, W. Brugger, W. Freier, 2011, British Journal of Cancer.

Germ cell tumor (GCT): Staging and therapy control with 18FDG-PET. First results of German multicenter trial

C. Bokemeyer, G. Jakse, R. Bares, 1997 .